In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

نویسندگان

  • Fanny Angelot-Delettre
  • Anne Roggy
  • Arthur E Frankel
  • Baptiste Lamarthee
  • Estelle Seilles
  • Sabeha Biichle
  • Bernard Royer
  • Eric Deconinck
  • Eric K Rowinsky
  • Christopher Brooks
  • Valerie Bardet
  • Blandine Benet
  • Hind Bennani
  • Zehaira Benseddik
  • Agathe Debliquis
  • Daniel Lusina
  • Mikael Roussel
  • Françoise Solly
  • Michel Ticchioni
  • Philippe Saas
  • Francine Garnache-Ottou
چکیده

Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of interleukin-3 receptor α chain (IL3-Rα or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dose-dependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentrations than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated controls (median survival, 58 versus 17 days, P<0.001). These findings indicate that blastic plasmacytoid dendritic cell neoplasm cells are highly sensitive to SL-401, and support further evaluation of SL-401 in patients suffering from blastic plasmacytoid dendritic cell neoplasm.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Blastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy that is known to be derived from plasmacytoid dendritic cells which are characterized by expression of CD4, CD56, and more specific markers such as CD123. Here, the authors present three cases of BPDCN diagnosed in the past two years and address different available diagnostic modalities such as morpho...

متن کامل

Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promising approach since blastic plasmacytoid dendritic cell neoplasm has been reported to exhibit constitutive activation of this pathway. Moreover, nu...

متن کامل

Cancer Therapy: Preclinical Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm

Purpose: Blastic natural killer (NK) cell lymphoma/blastic plasmacytoid dendritic cell neoplasm (BNKL) is a rare and aggressive neoplasia characterized by infiltration of blast CD4þ/CD56þ cells in the skin, the bone marrow, and peripheral blood. Currently, more efforts are required to better define molecular and biological mechanisms associated with this pathology. To the best of our knowledge,...

متن کامل

Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia.

A 64-year-old man presented with progressive skin lesions, which were diagnosed as blastic plasmacytoid dendritic cell neoplasm (BPDCN) and were confirmed with marrow involvement. He received SL-401 chemotherapy but developed persistent monocytosis. A 3-month follow-up bone marrow biopsy showed characteristic “tadpole” cells on smears (panels A-B; original magnifications 3500, hematoxylin and e...

متن کامل

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Case of Multiple, Painless, Erythematous Nodule on the Back

Blastic plasmacytoid dendritic cell neoplasm is a rare, highly aggressive hematopoietic malignancy that is characterized by the clonal proliferation of immature or precursors of plasmacytoid dendritic cells. We report the case of 70-year-old woman affected by blastic plasmacytoid dendritic cell neoplasm who died despite 6 months of chemotherapy.

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Haematologica

دوره 100 2  شماره 

صفحات  -

تاریخ انتشار 2015